NextCell Pharma publish Interim Report 1 2024/2025

January 30, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

First Quarter (2024-09-01 to 2024-11-30)

Operating income amounted to 2,864 (4,695) TSEK, of which Cellaviva contributed 2,828 (4,246) TSEK.
Net sales amounted to 2,828 (4,246) TSEK.
Profit/loss after financial items amounted to -8,042 (-9,796) TSEK.
Earnings per share* were -0.11 (-0.28) SEK.
Cash and cash equivalents amounted to 34,123 (40,428) TSEK.
Equity ratio** amounted to 86 (81) percent.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the first quarter of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 30 November 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the first quarter

At the beginning of September, the Company presented new clinical long-term data at the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting. The results demonstrate the long-term safety and efficacy of the treatment in preserving endogenous insulin production, along with additional health benefits for patients with type 1 diabetes (T1D), such as lower BMI and blood pressure.
At the end of September, the Company announced that the first four children in the 7–11 age group had been treated in the latest phase of the ProTrans-Young study, with an additional four children screened and expected to begin treatment shortly. These developments mark a significant milestone in the study, which is progressing faster than anticipated.
In early October, the Company announced that ProTrans was highlighted as a promising treatment for type 1 diabetes in Dagens Medicin.
In early November, NextCell Pharma participated in BIO-Europe 2024, one of Europe’s most important partnering conferences in biotechnology and pharmaceutical development, which was attended by Sweden's Minister for Energy and Enterprise and Deputy Prime Minister, Ebba Busch.
At the end of November, QVance, a subsidiary of NextCell Pharma, announced two significant partnerships with bioMérieux Sweden and Royal International.
In late November, the Company announced that Eva Sjökvist Saers was elected as a new board member at the Annual General Meeting.

Significant events after the reporting period

In December, NextCell reported new results from the ProTrans-Repeat study. "The results from the ProTrans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," commented Mathias Svahn, CEO.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on
30th January 2025, 08.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 0+46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For information about Cellaviva, please contact:

Sofie Falk Jansson, CEO

Tel: 08-735 2010

E-mail: info@cellaviva.se

Website: www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige

Twitter: https://www.instagram.com/cellaviva/

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachment Read full press release on Cision (external link)

2018-03-06

NextCell CEO invited speaker at the Swedish National ATMP Conference

NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 1st Swedish National Advanced Therapy Medicinal Product Conference held in Lund on March 15th. The topic of the lecture will be ‘Mesenchymal Stem Cells in Clinical Trials for Treatment of Autoimmune Diseases’. More specifically it describes, how NXTCL leads the way with the development of its drug candidate, ProTrans, using pooled mesenchymal stem cells form the umbilical cord. NXTCL is currently conducting a phase I/II trial using its drug candidate ProTrans for the treatment of adult

Read more Read more

2018-02-22

Three patients now treated with NextCells ProTrans stem cells

NextCell Pharma AB ("NXTCL") announces that three type 1 diabetes patients have been treated with ProTrans in the ongoing clinical phase I/II trial. Thus, all patients in the low-dose-cohort have now undergone treatment. The trial performed with NXCTCL's patent-pending ProTrans, is divided into two parts, the first part being a doseescalation phase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Now that all patients in the low-dose-cohort have been treated and after the 1-month follow-up is completed we can start inclusion of patients in the

Read more Read more

2018-02-16

NextCell Pharma files patent application

NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans. The selection algorithm is based on multiple functional assays used to identify and select cells and donors with specified desired characteristics. ProTrans is a pooled allogeneic stem cell product, consisting of cells from multiple donors. The pooling process supports the production of large batches. The combination

Read more Read more

2018-01-31

NextCell Pharma changes ticker to NXTCL

NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL. Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has decided to change the ticker to NXTCL. The new abbreviation might also be used in general market communications and company branding. The new ticker will become effective as per 2018-02-07, the company name and ISIN-code (SE0009723125) will remain the same. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation.

Read more Read more

2018-01-24

First diabetes patient treated with ProTrans stem cells

NextCell Pharma AB ("NextCell") announces that the first patient with type 1 diabetes has now been treated with the company's drug candidate ProTrans. The clinical trial evaluates the safety and efficacy of ProTrans after treatment of patients 18-40 years old and who had type 1 diabetes for a maximum of two years. The clinical trial started on November 28th, 2017 and after clinical assessment and baseline data collection, the first patient has now been treated (first-in-human) with ProTrans stem cells. The first part of the study is a three-step dose escalation with three patients in each

Read more Read more

2017-11-29

NextCell Pharma initiates stem cell trial for type 1-diabetes with ProTrans

NextCell Pharma AB ("NextCell") announces that the initiation meeting for the clinical trial in which drug candidate ProTrans will be evaluated, was held on November 28th, 2017. The trial will investigate safety as well as evaluate the patient’s own insulin production 12 months after receiving ProTrans stem cell treatment. Patients with type 1-diabetes being 18-40 years who received their diagnosis no later than 2 years ago and still have some insulin production are candidates for participation in the trial. NextCell Pharma has reached a new level as a company. I would like to thank all the

Read more Read more

2017-11-14

Today Nextcell Pharma publishes its annual report 2016-2017

NextCell Pharma AB (publ) hereby publishes the annual report for the financial year 2016/2017. The annual report is attached to this press release and can be downloaded from the company's website www.nextcellpharma.com

Read more Read more

2017-10-31

NextCell Pharma updates on its situation in its fourth quarter report

NextCell Pharma AB ("NEXTCL", "NextCell") today releases its Q4 / year-end report (June 1st - August 31st / September 1st - August 31st). This is the first quarterly report since the listing on Aktietorget. The company reports a loss of SEK -4,757,996 in its fourth quarter and a loss of SEK -13,245,206 for the entire financial year. The remaining cash at August 31st was approximately 16 MSEK. The perhaps most important event during the fourth quarter was the listing on Aktietorget on July 13th and the associated listing issue, which was subscribed to approximately 18 MSEK, corresponding to

Read more Read more